Adjuvant was established to scale the impact investment model developed at the Global Health Investment Fund (GHIF).

Working with a larger capital base, Adjuvant will strive to deliver top-tier financial returns to its investors without making any compromises on the original impact investment strategy pioneered at GHIF, where all successfully developed products must be accessible to those most in need in low- and middle-income countries.

Rather than being at odds with each other, these double-bottom-line objectives position Adjuvant to be at the forefront of the next generation of life sciences technologies, which need to consider rapidly evolving public health trends alongside the needs of the billions of emerging economy consumers who are pursuing universal health equity.